Imara M&A

ELVN-002: Opportunity for a Selective Irreversible Pan-Mutant HER2 TKI Current HER2 TKI Landscape • The high degree of structural homology between EGFR and HER2 makes it difficult to design HER2-selective inhibitors • Most approved and investigational agents are dual EGFR/HER2 inhibitors that are dose-limited by EGFR-driven toxicity ● ● Tucatinib is the only approved HER2-selective TKI, but lacks potency against key mutants, including HER2 YVMA, the most common Exon 20 insertion mutation (E201M) in NSCLC, and L755, the most common HER2 breast cancer mutation Current HER2 TKIs do not achieve sufficient CNS free drug levels to address brain metastases, leading to disease progression in patients with lung and breast cancer Our HER2 Candidate: ELVN-002 CNS = Central nervous. IM Insertion mutation. NSCLC = Non-small cell lung caner. TKI = Tyrosine kinase inhibitor. NHP = non-human primate. ● Designed to irreversibly inhibit HER2 and multiple key HER2 mutations, including HER2 YVMA and L755, and Selectively inhibit HER2 while sparing EGFR to prevent EGFR-related toxicities, with the potential for improved efficacy in NSCLC and other cancers Demonstrated superior pre-clinical activity in HER2- amplified subcutaneous and intracranial models, and an improved safety margin in NHPs compared to tucatinib We believe that our product candidate, if it achieves the target profile, will be able to achieve an improved therapeutic index compared to current approved and investigational TKIs as well as provide a meaningful therapeutic option to patients with brain metastases 13

View entire presentation